{
    "title": "103_s1249",
    "content": "The Act may be cited as the \"Tuberculosis Prevention and Control Amendments of 1993\". Between 10,000,000 and 15,000,000 people in the United States have been infected with tuberculosis, with nearly 26,000 new cases reported annually and over 1,700 deaths each year. The number of reported cases has increased from 22,201 in 1985 to 26,673 in 1992, with drug-resistant strains costing more. In 1992, a national survey found 14.4% of active tuberculosis cases were resistant to at least one drug, costing over $150,000 to treat with a high mortality rate. Cases were reported in all 50 states, with drug-resistant cases in 36 states, DC, and Puerto Rico. In 1992, tuberculosis cases were reported in all 50 states, with drug-resistant cases in 36 states, DC, and Puerto Rico. 27% of cases occurred in foreign-born persons. One third of the world's population harbors tuberculosis, making it the number one killer among infectious diseases with 8,000,000 new cases and 2,900,000 deaths annually. SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL AND PREVENTION. The amendment to the Public Health Service Act includes increased funding for prevention, control, and elimination services for fiscal years 1994-1997. Additionally, a new paragraph is added regarding State Tuberculosis Plan applications for grants. The Public Health Service Act is amended to include a new paragraph requiring State plans for tuberculosis prevention grants to target high-risk populations or areas with high infection rates. State plans for tuberculosis prevention grants must target high-risk populations or areas with high infection rates. Plans should involve collaboration with entities receiving funds under various sections and use grant funds for effective interventions for populations with high rates of active tuberculosis infection. State plans for tuberculosis prevention grants must target high-risk populations or areas with high infection rates. Plans should involve collaboration with entities receiving funds under various sections and use grant funds for directly observed therapy or other effective interventions for populations with the highest rates of active tuberculosis infection. The Secretary may conduct or support research and training on tuberculosis prevention, control, and treatment. $26,000,000 is authorized for fiscal year 1994. The Secretary may conduct or support research and training on tuberculosis prevention, control, and treatment, with $26,000,000 authorized for fiscal year 1994. Additional appropriations are authorized for fiscal years 1995 through 1997. A technical amendment is made to Section 317(j)(2) of the Public Health Service Act. Research and research training regarding tuberculosis is to be conducted through the National Institute of Allergy and Infectious Diseases. The National Institute of Allergy and Infectious Diseases will conduct or support research on the cause, diagnosis, early detection, and treatment of tuberculosis. Amendments are made to sections 446 and 408(a) of the Public Health Service Act to authorize appropriations for this purpose. The National Institute of Allergy and Infectious Diseases will conduct research on tuberculosis. Authorization of appropriations for this research is made in section 408(a) of the Public Health Service Act. $46,000,000 is authorized for fiscal year 1994, with additional funding for the following years. The National Institute of Allergy and Infectious Diseases authorized $46,000,000 for fiscal year 1994 and additional funding for fiscal years 1995 through 1997. The authorization of appropriations does not terminate availability for other funding sources. SEC. 5. RESEARCH THROUGH THE FOOD AND DRUG ADMINISTRATION. A new section, SEC. 512A, is added to the Food, Drug and Cosmetic Act for Tuberculosis drug and device research. The Commissioner of Food and Drugs will implement a tuberculosis drug and device research program, providing assistance for protocol development, reviewing medical devices for tuberculosis diagnosis, and conducting research on drugs and devices. $5,000,000 is authorized for this program annually."
}